Patient must have valid Social Security number to apply for assistance and receive treatment in the United States.
Patient income must be at or below 500% of the Federal Poverty Level (FPL.)
Patient is required to have insurance coverage which covers at least 50% of the cost of treatment.
Patient must be diagnosed with a covered disease and program must be accepting enrollments.
Patient must be seeking assistance for a prescribed medication that is FDA approved to treat the covered diagnosis.
Abiraterone
Abirtega
Asmalpred
Beizray
Docefrez
Docetaxel
Docivyx
Firmagon
Jevtana
Keytruda
Lynparza
Medicort
Millipred
Orapred
Orapred ODT
Pediapred
Pluvicto
Prednisolone
Provenge
Rubraca
Talzenna
Taxotere
Vitrakvi
Xofigo
Xtandi
Yonsa
Zytiga
Prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels. Many early-stage prostate cancers need normal levels of testosterone to grow, but castrate-resistant prostate cancers do not. (Source: NIH; National Cancer Institute)
Eligibility Criteria
Patient must have valid Social Security number to apply for assistance and receive treatment in the United States.
Patient income must be at or below 500% of the Federal Poverty Level (FPL.)
Patient is required to have insurance coverage which covers at least 50% of the cost of treatment.
Patient must be diagnosed with a covered disease and program must be accepting enrollments.
Patient must be seeking assistance for a prescribed medication that is FDA approved to treat the covered diagnosis.
Medications Covered
Abiraterone
Abirtega
Asmalpred
Beizray
Docefrez
Docetaxel
Docivyx
Firmagon
Jevtana
Keytruda
Lynparza
Medicort
Millipred
Orapred
Orapred ODT
Pediapred
Pluvicto
Prednisolone
Provenge
Rubraca
Talzenna
Taxotere
Vitrakvi
Xofigo
Xtandi
Yonsa
Zytiga
Disease Description
Prostate cancer that keeps growing even when the amount of testosterone in the body is reduced to very low levels. Many early-stage prostate cancers need normal levels of testosterone to grow, but castrate-resistant prostate cancers do not. (Source: NIH; National Cancer Institute)